抗新生血管生成药(贝伐单抗)治疗翼状胬肉的研究现状  

Research Status of Anti-vascular Endothelial Growth Factors( Bevacizumab) Treating Pterygia

作　　者：张蒙[1] 陈子林[2] 

机构地区：[1]中山大学第二临床学院,广州510000 [2]惠州市中心人民医院眼科中心,广东惠州516001

出　　处：《医学综述》2014年第1期109-111,共3页Medical Recapitulate

摘　　要：翼状胬肉是鼻侧球结膜下的纤维组织肥厚增生呈翼状侵入角膜的一种疾病,目前缺乏统一的治疗方法。最近研究发现,血管内皮生长因子(VEGF)引导的新生血管形成在翼状胬肉发病机制中占主导地位。抗VEGF药物具有抑制新生血管、减少渗出的作用,被广泛应用于以新生血管再生为特点的眼后段疾病,同时也为翼状胬肉提供了新的治疗手段。Pterygia is characterized by the encroachment of a fleshy fibrovascular tissue from the bulbar conjunctiva into the cornea, but the treatment is presently uncertain. Recently, many papers suggest VEGF inducing angiogenesis playes an important role in the patbogenesis of pterygia. Anti-angiogenesis agents with the function of angiogenesis inhibition and exudation reduction have mainly been widely used in the posterior segment ocular diseases characterized by neovascularization, which also provides a new treatment for pterygia.

关 键 词：抗血管新生药 贝伐单抗 翼状胬肉 

分 类 号：R777[医药卫生—眼科]